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hel lenic- journal-of-cardiology/EDITORIALLong-term follow-up of patients with
implantable cardioverter defibrillators
in Greece: The Cretan RegistryIn the current issue of the Journal, Kanoupakis, et al.1
present long-term data on mortality and utilization of
device therapies in their cohort of primary and secondary
prevention implantable cardioverter defibrillator (ICD)
recipients on the island of Crete. This is an important
registry including data from the only ICD implantation
center in Crete, and these data are sufficiently robust to
be considered representative of Greece. Actually, the
number of ICD implantations performed at Heraklion
University Hospital during the past five years exceeded
the respective number of ICD implantations performed
per million population in Greece, as evidenced by the
published EHRA White Books.2 Moreover, the indications,
clinical outcomes, delivered therapies and adverse
events identified in this cohort of ICD recipients were in
accordance with those reported by other international
centers.
The ICD is the most effective therapy currently avail-
able to prevent sudden cardiac death (SCD).3,4 ICD im-
plantation rates are increasing worldwide.5 This increase
was driven by secondary prophylaxis ICDs until 2006 and
primary prevention ICDs thereafter.5,6 The Cretan Regis-
try is in accordance with European Guidelines and current
cardiovascular practice. Large randomized trials have
demonstrated that ICD implantation was associated with
improved survival through the achievement of primary
and secondary SCD prevention. The long-term efficacy
of ICD treatment was supported by the findings of an
extended 11-year follow-up of a subgroup of the sec-
ondary prevention population included in the Canadian
Implantable Defibrillator Study (CIDS), which enrolled
patients with sustained ventricular arrhythmias combined
with hemodynamic instability or reduced left ventricular
ejection fraction (LVEF).7 Long-term ICD treatment (8Peer review under responsibility of Hellenic Cardiological
Society.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).years of follow-up) was also deemed effective in the
primary prevention population included in the second
Multicenter Automatic Defibrillator Implantation Trial
(MADIT-II).8 These randomized trials were performed in
defined patient populations and, therefore, may not be
representative of everyday clinical practice. The few
long-term survival outcomes that have been reported in
patients outside the clinical trial setting include those
identified in a cohort of 270 patients with an ICD
implanted for life-threatening arrhythmias in the United
States in the early 1980s, and this study reported all-
cause mortality rates at 1 and 5 years to be 8% and 26%,
respectively.9 Similar mortality rates were reported by
the ALTITUDE project, which included data from >2,000
centers across the United States, with mortality rates of
8% identified at 1 year (12% for cardiac resynchronization
therapy-defibrillator patients) and 32% identified at 5
years among ICD patients.10 The Australian Registry re-
ported 74% and 53% survival rates at 5 and 10 years,
respectively.11 Similar findings were reported by Leiden
University,12 the Danish,6 and the current Cretan
registry.1
The incidence of all-cause mortality in the Cretan
registry was observed to be significantly higher in the
group of secondary prevention patients than the group of
primary prevention patients over a mean follow-up period
of 11.2  7.8 years.1 Similar findings were reported by
Leiden University after an 8-year of follow-up of their ICD
recipients,12 whereas comparable all-cause mortality
trends in the two groups were observed during the first 3
years of follow-up.12,13
Moreover, secondary prevention ICD recipients in Crete
were found to have a higher prevalence of appropriately
delivered therapies relative to primary prevention ICD
recipients.1 Similar findings have been reported pre-
viously.12e14 Appropriate ICD therapies (particularly
delivered shocks) were identified as significantlyElsevier B.V. This is an open access article under the CC BY-NC-ND
254 Editorialassociated with increased long-term mortality rates in the
secondary prevention ICD group. This observation was of
considerable significance, as a sizeable proportion of
patients with ICDs received appropriate intervention
during follow-up. Indeed, data suggest that a total of
20e35% of heart failure (HF) patients who receive an ICD
for primary prevention and 35e45% of HF patients who
receive an ICD for secondary prevention of SCD are pre-
dicted to receive an appropriate shock for a life-
threatening arrhythmia within 1e3 years.15,16 Until now,
efforts have been directed at preventing both appropriate
and inappropriate ICD shocks. Several therapeutic options
that may be used to achieve a reduction in ICD shocks are
available, including medications, ICD reprogramming, and
prophylactic catheter ablation before ICD implantation.17
An important meta-analysis comparing ICD therapy
reduction programming and conventional programming
reported reduction programming to be associated with a
significant reduction in mortality.18 However, this
decrease was mainly driven by a reduction in inappro-
priate, rather than appropriate, shocks. Nevertheless, the
increased mortality observed in association with ICD
delivered therapies has been considered to occur inde-
pendent of the modality of ICD intervention,19 suggesting
a negative effect of ventricular arrhythmia episodes on
mortality risk or, alternatively, that ventricular arrhyth-
mias may be a marker of more advanced heart disease.
Therefore, we should still seek to reduce unnecessary ICD
therapies and their associated adverse psychological ef-
fects. However, in the case of increased risk after ICD
shock, it is the occurrence of an associated arrhythmia in
a vulnerable myocardium or vulnerable patient that likely
explains the increased cardiovascular risk and not the
shock itself.
Important ICD registries, such as the one described by
Kanoupakis, et al.,1 may significantly enhance our under-
standing of the validity and limitations of ICDs20,21 and
serve as a solid basis for the deployment of long-term
nationwide reports.
Conflict of interest
The authors have no potential conflict of interest to
declare.
Funding
None.
References
1. Kanoupakis EM, Fanourgiakis JA, Mavrakis HE, et al. Long term
clinical outcome of implantable cardioverter defibrillator re-
cipients in the island of Crete. Hellenic J Cardiol. 2016.
2. Raatikainen MJ, Arnar DO, Zeppenfeld K, Merino JL,
Kuck KH, Hindricks G. Current trends in the use of cardiac
implantable electronic devices and interventional electro-
physiological procedures in the European Society of Cardi-
ology member countries: 2015 report from the European
Heart Rhythm Association. Europace. 2015 Aug;17(suppl 4):
iv1eiv72.3. Moss AJ, Hall WJ, Cannom DS, et al, Multicenter Automatic
Defibrillator Implantation Trial Investigators. Improved survival
with an implanted defibrillator in patients with coronary dis-
ease at high risk for ventricular arrhythmia. N Engl J Med.
1996;335:1933e1940.
4. Al-Khatib SM, Hellkamp AS, Fonarow GC, et al. Association
between prophylactic implantable cardioverter-defibrillators
and survival in patients with left ventricular ejection fraction
between 30% and 35%. JAMA. 2014 Jun 4;311(21):2209e2215.
5. Arribas F, Auricchio A, Boriani G, et al. Statistics on the use of
cardiac electronic devices and electrophysiological procedures
in 55 ESC countries: 2013 report from the European Heart
Rhythm Association (EHRA). Europace. 2014 Apr;16(suppl 1):
i1ei78.
6. Schmidt M, Pedersen SB, Farkas DK, et al. Thirteen-year
nationwide trends in use of implantable cardioverter-
defibrillators and subsequent long-term survival. Heart
Rhythm. 2015 Sep;12(9):2018e2027.
7. Bokhari F, Newman D, Greene M, Korley V, Mangat I, Dorian P.
Long-term comparison of the implantable cardioverter defi-
brillator versus amiodarone: eleven-year follow-up of a subset
of patients in the Canadian Implantable Defibrillator Study
(CIDS). Circulation. 2004;110:112e116.
8. Goldenberg I, Gillespie J, Moss AJ, et al, Executive Committee
of the Multicenter Automatic Defibrillator Implantation Trial II.
Long-term benefit of primary prevention with an implantable
cardioverter-defibrillator: an extended 8-year follow-up study
of the Multicenter Automatic Defibrillator Implantation Trial II.
Circulation. 2010 Sep 28;122(13):1265e1271.
9. Winkle RA, Mead RH, Ruder MA, et al. Long-term outcome with
the automatic implantable cardioverter-defibrillator. J Am Coll
Cardiol. 1989 May;13(6):1353e1361.
10. Saxon LA, Hayes DL, Gilliam FR, et al. Long-term outcome after
ICD and CRT implantation and influence of remote device
follow-up: the ALTITUDE survival study. Circulation. 2010 Dec
7;122(23):2359e2367.
11. Bradshaw PJ, Stobie P, Briffa T, Hobbs MS. Use and long-term
outcomes of implantable cardioverter-defibrillators, 1990 to
2009. Am Heart J. 2013 May;165(5):816e822.
12. van der Heijden AC, Borleffs CJ, Buiten MS, et al. The clinical
course of patients with implantable cardioverter-defibrillators:
extended experience on clinical outcome, device re-
placements, and device-related complications. Heart Rhythm.
2015 Jun;12(6):1169e1176.
13. van Welsenes GH, van Rees JB, Borleffs CJ, et al. Long-term
follow-up of primary and secondary prevention implantable
cardioverter defibrillator patients. Europace. 2011 Mar;13(3):
389e394.
14. Borleffs CJ, van Erven L, Schotman M, et al. Recurrence of
ventricular arrhythmias in ischaemic secondary prevention
implantable cardioverter defibrillator recipients: long-term
follow-up of the Leiden out-of-hospital cardiac arrest study
(LOHCAT). Eur Heart J. 2009;30:1621e1626.
15. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update:
ACCF/AHA Guidelines for the diagnosis and management of
heart failure in adults: a report of the American College of
Cardiology Foundation/American Heart Association Task Force
on Practice Guidelines: developed in collaboration with the
International Society for Heart and Lung Transplantation. Cir-
culation. 2009;119:1977e2016.
16. Dickstein K, Vardas PE, Auricchio A, et al. ESC Committee for
Practice Guidelines: 2010 focused update of ESC Guidelines on
device therapy in heart failure: an update of the 2008 ESC
Guidelines for the diagnosis and treatment of acute and
chronic heart failure and the 2007 ESC Guidelines for cardiac
and resynchronization therapy. Developed with the special
contribution of the Heart FailureAssociation and the European
Heart Rhythm Association. Europace. 2010;12:1526e1536.
Editorial 25517. Proietti R, Labos C, Davis M, et al. A systematic review and
meta-analysis of the association between implantable
cardioverter-defibrillator shocks and long-term mortality. Can
J Cardiol. 2015 Mar;31(3):270e277.
18. Tan VH, Wilton SB, Kuriachan V, Sumner GL, Exner DV. Impact
of programming strategies aimed at reducing nonessential
implantable cardioverter-defibrillator therapies on mortality:
a systematic review and meta-analysis. Circ Arrhyth Electro-
physiol. 2014;7:164e170.
19. Bencardino G, Di Monaco A, Rio T, et al. The association be-
tween ICD interventions and mortality is independent of their
modality: clinical implications. J Cardiovasc Electrophysiol.
2014 Dec;25(12):1363e1367.
20. Fanourgiakis J, Simantirakis E, Maniadakis N, et al. Complica-
tions related to cardiac rhythm management device therapy
and their financial implication: a prospective single-center two
year survey. Hellenic J Cardiol. 2016 Jan-Feb;57(1):33e38.
21. Stabile G, Gallo P, La Rocca V, et al. Inducibility of ventricular
arrhythmia and tachyarrhythmia recurrences in patients withimplantable defibrillator. Hellenic J Cardiol. 2015 May-Jun;
56(3):230e236.
Polychronis Dilaveris*
Dimitris Tousoulis
From the First Department of Cardiology,
University of Athens Medical School,
Hippokration Hospital, Athens, Greece*Corresponding author. Polychronis Dilaveris, MD, PhD, FESC
22 Miltiadou Street, 155 61 Holargos, Athens, Greece.
Tel./fax: þ30 210 6531 377.
E-mail address: hrodil1@yahoo.com (P. Dilaveris)
Available online 17 September 2016
